The 2025 Chinese expert consensus on transcatheter aortic valve replacement provides updated, evidence-based recommendations for its standardized application and management in clinical practice.
This 2025 Chinese expert consensus provides updated, evidence-based recommendations for the standardized application of TAVR in China.
Transcatheter aortic valve replacement (TAVR), also known as transcatheter aortic valve implantation (TAVI), is an interventional technology in which an artificial aortic valve is compressed and assembled outside the body, then delivered through a catheter and implanted at the site of the diseased aortic valve, thereby functionally replacing the native valve. Two versions of the Chinese expert consensus on TAVR were issued in China in 2015 and 2020, respectively. To promptly update the field’s understanding of TAVR and to promote its broader, more standardized, and higher-quality application in China, an expert panel has developed this new version of the consensus. This consensus includes substantial updates compared with the previous version, covering topics such as the epidemiology of aortic valve disease, recent advances in TAVR research, indications, procedural standards, post-procedural antithrombotic therapy, prevention and management of complications, management of special cases, and future development trends. This consensus integrates international research evidence and references international guidelines to ensure rigor and evidence-based recommendations, while also incorporating domestic research findings and clinical practice in China, thereby enhancing both its forward-looking perspective and practical applicability.
A Mon, study conducted a review in Aortic valve disease. Transcatheter aortic valve replacement (TAVR) was evaluated. The 2025 Chinese expert consensus on transcatheter aortic valve replacement provides updated, evidence-based recommendations for its standardized application and management in clinical practice.